Steatohepatitis/Metabolic Liver Disease News

Alcohol use was a significant risk factor for clinically defined nonalcoholic fatty liver disease due to association with alcohol use and liver fat, according to recently published data.

Galectin Therapeutics announced plans for a phase 3 clinical trial of belapectin for patients with nonalcoholic steatohepatitis-related cirrhosis without esophageal varices, according to a press release.

LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, discusses a new artificial intelligence and machine learning tool for nonalcoholic fatty liver disease prediction.

BOSTON — In this exclusive video from The Liver Meeting 2019, Manu Chakravarthy, MD, PhD, chief medical officer and senior vice president of Axcella Health, discusses positive study results from two product candidates including one for nonalcoholic fatty liver disease and one for cirrhosis.

BOSTON — In this exclusive video from The Liver Meeting 2019, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax Hospital in Virginia, provides an overview of patient reported outcomes from several studies of emerging nonalcoholic fatty liver disease and nonalcoholic steatohepatitis therapies.

Women who developed nonalcoholic fatty liver disease no longer retained the cardiovascular protective effect conferred by female sex, according to a study published in American Journal of Gastroenterology.

Viking Therapeutics announced the initiation of a phase 2b trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist undergoing investigation for patients with nonalcoholic steatohepatitis, according to a press release.

BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, highlights new data on emerging therapeutics for nonalcoholic steatohepatitis presented at the meeting.

The FDA accepted the first new drug application for the treatment of liver fibrosis due to nonalcoholic steatohepatitis; Intercept announced that obeticholic acid, already approved for the treatment of primary biliary cholangitis under the brand Ocaliva, has a PDUFA date of March 26, 2020.

BOSTON — In this exclusive video from The Liver Meeting 2019, Vlad Ratziu, MD, PhD, professor of hepatology at Sorbonne University and Pitié-Salpêtrière Hospital, discusses his poster presentation on the diagnostic aspects of nonalcoholic steatohepatitis in patients with type 2 diabetes.